# First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

> **NCT05163522** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 73 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** VH4004280
- **DRUG:** Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT05163522
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2023-06-21
- **Final completion:** 2023-06-21
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05163522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05163522, "First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05163522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*